1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 4: Clinical and imaging outcomes according to the presence/absence of a subarachnoid hemorrhage at presentation
Variable Total (No.) (%) Unruptured (No.) (%) Ruptured (No.) (%) P Value
Clinical outcomes 
    Total treatments 93 81 (87) 12 (13) 
    Mortality 0 0 (0) 0 (0) 1.000
    Morbidity 4 (4) 3 (3) 1 (8) .430
        Infarction 3 (3) 2 (2) 1 (8) .343
        Hydrocephalus 1 (1) 1 (1) 0 (0) 1.000
Visual outcomes 
    Total patients 65 54 (83) 11 (17) 
    Visual disturbance at presentation 22 (34) 21 (39) 1 (9) .082
    Visual disturbance after treatment .03
        Improved 15 (68) 15 (71) 0 (0) 
        Unchanged 5 (22) 4 (27) 1 (100) 
        Worse 2 (9) 2 (9) 0 (0) 
        New (% of all patients) 1 (2) 0 (0) 1 (9) 
Imaging outcomes 
    Aneurysms 65 53 (82) 12 (18) 
        Primary occlusion 35 (55) 30 (58) 5 (42) .523
    Aneurysms with >12 months' follow-up 53 45 8 .211
        Retreatment 16 (30) 10 (22) 6 (75) .0007^{^a}
        Progressive occlusion 2 (4) 2 (4) 0 (0) 
        Unchanged 34 (64) 33 (73) 2 (25) 
↵a Retreatment-versus-progressive occlusion/unchanged.